Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

Stopped Overall profile of the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents

Conditions

• Hypercholesterolemia

Interventions

• DRUG: Lapaquistat acetate and current lipid-lowering treatment
• DRUG: Current lipid-lowering treatment

Sponsor

Takeda